Agathos Biologics @AgathosBio

🔬 Join us at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, where Agathos Biologics unveils groundbreaking data on our AE1-BHK cell line for viral vector production! #ASGCT #genetherapy agathos.bio/agathos-biolog…

🌟 BREAKTHROUGH NEWS 🌟 The FDA has approved Lenmeldy, the first gene therapy for children with Metachromatic Leukodystrophy (MLD). This treatment offers hope to those affected by this rare genetic disease. #genetherapy fda.gov/news-events/pr…

🔬 Breaking News: Agathos Biologics launches recombinant adeno-associated virus production (rAAV) service using novel AE1-BHK cell line agathos.bio/agathos-biolog… #genetherapy #viralvectors

🌍 Today, on Rare Disease Day, we stand with 300 million individuals worldwide facing the challenges of rare diseases. Since 2008, this global movement has united communities, advocating for equitable healthcare, timely diagnosis, and accessible treatments. #RareDiseaseDay2024

A recent study published in Cellular Reprogramming reveals promising results in extending lifespan and reversing age-related changes in mice using gene therapy-mediated partial reprogramming. liebertpub.com/doi/10.1089/ce…… #genetherapy #aav #biotech

🔬✨ Illuminate the intricacies of cellular biology with Agathos Biologics' advanced imaging techniques! Our high-throughput, multiparametric cell painting service enables you to delve deep into the inner workings of cells like never before. Contact us today! [email protected]

Gene Therapy Restores Hearing Loss in 11-Year-Old After Just One Month! 🌟 Akouos, a subsidiary of Eli Lilly, achieves groundbreaking success in the AK-OTOF-101 study. Witness the transformative power of gene therapy: genengnews.com/topics/transla… #GeneTherapy

According to DelveInsight Business Research LLP, AAV gene therapy is poised for significant growth and continues to be a promising space for transformative advancements. #genetherapy finance.yahoo.com/news/aav-vecto…

Gene therapy, led by adeno-associated viruses, holds promise for tackling hepatocellular carcinoma. Despite lacking specific trials, AAVs' safety and efficacy in diverse diseases hint at a revolutionary path in liver cancer treatment. #GeneTherapy virologyj.biomedcentral.com/articles/10.11…

Researchers at Indiana University School of Medicine have discovered a game-changing liver pathway that may pave the way for change in immunomodulation strategies for gene therapy. medicalxpress.com/news/2023-12-r… #aav #GeneTherapy

AskBio to begin the first subjects in Phase I AAV gene therapy trial. The AB-1005 gene therapy is being analyzed for the treatment Parkinson’s disease. Looking forward to the outcomes and the positive impact on patients' lives! clinicaltrialsarena.com/news/askbio-ge… #genetherapy

Elevate your AAV research to new heights with Agathos' Analytical Services! 🧬 Unlock the power of precise AAV titering through our cutting-edge dPCR technology, setting the gold standard for accuracy in quantification. agathos.bio/analytical-ser… #ViralVector #GeneTherapy

US Pharmacopeia has published <1040> Quality Considerations for Plasmid DNA as a Starting Material for Cell and Gene Therapies. Agathos CEO @JWBrownPhD participated in the Expert Panel that developed the draft. Please consider commenting! doi.usp.org/USPNF/USPNF_M1…

Concordia College receives a $2.5 million NSF grant for STEM scholarships. Agathos is proud to support the CLIMB program, which prepares students for impactful careers in the rapidly growing biotechnology sector. concordiacollege.edu/news/release-d… #Fargo #stem #northdakota #concordiacollege

Agathos Biologics' CEO, James Brown, presented at the Alliance for Regenerative Medicine's Meeting on the Mesa and highlighted Agathos' ongoing efforts in creating innovative cell lines to produce adeno-associated viruses. youtube.com/watch?v=DSb8_y… #meetingonthemesa #GeneTherapy

FAST (The Foundation for Angelman Syndrome Therapeutics) announced a research and development agreement with the University of Pennsylvania to develop an investigational adeno-associated virus (AAV) gene therapy for Angelman syndrome (AS). news-medical.net/news/20231017/…

Agathos Biologics is thrilled to participate in Curiosity Week, hosted by Emerging Prairie! Join us for an enlightening discussion on the future of bioscience in the FM Metro region. curiosityweek2023a.sched.com/event/1Pq3A/co… #fargo #emergingprairie #FMEDC #bioscience

Exciting News from Agathos Biologics! We're thrilled to announce that we've been awarded a $300,000 grant from the 2023 North Dakota Bioscience Innovation Grant Program. agathos.bio/agathos-biolog… #northdakota #genetherapy 🧬💡

Exciting news from UC Davis Health! They're pioneering a groundbreaking AAV-based gene therapy trial for Wilson Disease, a rare genetic disorder with no cure. This innovative AAV gene therapy could revolutionize treatment options. miragenews.com/uc-davis-healt… #GeneTherapy

A 5-year-old boy becomes the first in the nation to receive gene therapy for a rare disease. Jack's story is truly amazing! He is the first child in the United States to receive gene therapy for SPG50 using AAV9 to deliver the AP4M1 gene. wtnh.com/on-air/connect… #GeneTherapy